published meta-analysis   sensitivity analysis   studies

convalescent plasma treatment in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsBennett-Guerrero, 2021 0.86 [0.24; 3.11] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] 0.81[0.60; 1.08]Bennett-Guerrero, 2021, CONTAIN COVID-19, 2021, O’Donnell, 2021, PlasmAr, 202040%1,571moderatenot evaluable deathsdetailed resultsBaldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] CCAP-2, 2021 2.03 [0.61; 6.77] CONTAIN COVID-19, 2021 0.86 [0.60; 1.25] Libster, 2020 0.50 [0.09; 2.71] NCT04442191, 2021 0.11 [0.00; 143.68] O’Donnell, 2021 0.47 [0.21; 1.06] PlasmAr, 2020 0.93 [0.47; 1.85] 0.86[0.65; 1.13]Baldeon, 2022, Bennett-Guerrero, 2021, CCAP-2, 2021, CONTAIN COVID-19, 2021, Libster, 2020, NCT04442191, 2021, O’Donnell, 2021, PlasmAr, 202080%2,048moderatenot evaluable deaths (time to event analysis only)detailed resultsBaldeon, 2022 1.85 [0.49; 6.97] Bennett-Guerrero, 2021 0.80 [0.26; 2.45] PlasmAr, 2020 0.93 [0.47; 1.85] 1.01[0.59; 1.72]Baldeon, 2022, Bennett-Guerrero, 2021, PlasmAr, 202030%566lownot evaluable clinical deteriorationdetailed resultsCONTAIN COVID-19, 2021 0.94 [0.75; 1.18] Libster, 2020 0.52 [0.29; 0.94] 0.75[0.42; 1.31]CONTAIN COVID-19, 2021, Libster, 2020271%1,101moderatenot evaluable clinical improvementdetailed resultsBennett-Guerrero, 2021 0.75 [0.21; 2.68] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] 1.04[0.80; 1.37]Bennett-Guerrero, 2021, O’Donnell, 2021, PlasmAr, 202033%630lownot evaluable clinical improvement (28-day)detailed resultsBennett-Guerrero, 2021 1.02 [0.25; 4.20] O’Donnell, 2021 1.38 [0.73; 2.61] 1.31[0.73; 2.34]Bennett-Guerrero, 2021, O’Donnell, 202120%297lownot evaluable clinical improvement (time to event analysis only)detailed resultsBennett-Guerrero, 2021 0.75 [0.21; 2.68] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] 1.07[0.87; 1.32]Bennett-Guerrero, 2021, O’Donnell, 2021, PlasmAr, 202030%631lownot evaluable mechanical ventilationdetailed resultsO’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] 1.03[0.53; 2.00]O’Donnell, 2021, PlasmAr, 202020%556lownot evaluable ICU admissiondetailed resultsLibster, 2020 0.33 [0.07; 1.58] 0.33[0.07; 1.58]Libster, 202010%160NAnot evaluable serious adverse eventsdetailed resultsO’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] 0.95[0.44; 2.05]O’Donnell, 2021, PlasmAr, 2020270%552lownot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-03-29 14:41 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 538,957 - roots T: 290